Similar Search Results

The drugs economy and anti-drug policy in developing countries

Shams, Rasul - In: Intereconomics : review of European economic policy 27 (1992) 3, pp. 139-144

The drugs economy has now developed into a major factor in many developing countries. What effects on the economies of the countries concerned do drugs production and the drugs trade have? How should the prospects of success for substitution policies be judged? What strategy to curb the demand...

Persistent link: https://www.econbiz.de/10011546977

The drugs economy and anti-drug policy in developing countries

Shams, Rasul - In: Intereconomics : review of European economic policy 27 (1992) 3, pp. 139-144

Persistent link: https://www.econbiz.de/10001123860

Intellectual property rights and the evergreening of pharmaceuticals

Boscheck, Ralf - In: Intereconomics : review of European economic policy 50 (2015) 4, pp. 221-226

economies are fuelling calls to contain the so-called evergreening practices of drug producers around the world. But such … rights in general and the presumably special case of drug supplies. It focuses on strategies for extending the market … exclusivity for pharmaceuticals products and evaluates safeguards against such evergreening. …

Persistent link: https://www.econbiz.de/10011311672

Intellectual property marketplaces and how they work : evidence from German pharmaceutical firms

Andersen, Birgitte; Rossi, Federica; Stephan, Johannes - In: Intereconomics : review of European economic policy 45 (2010) 1, pp. 35-47

Persistent link: https://www.econbiz.de/10003931919

Intellectual property marketplaces and how they work : evidence from German pharmaceutical firms

Andersen, Birgitte; Rossi, Federica; Stephan, Johannes - In: Intereconomics : review of European economic policy 45 (2010) 1, pp. 35-47

This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...

Persistent link: https://www.econbiz.de/10009659550

Off-label drugs vs. the merits of centralised regulatory control

Boscheck, Ralf - In: Intereconomics : review of European economic policy 43 (2008) 5, pp. 277-281

Persistent link: https://www.econbiz.de/10003761054

Policy lessons from medical responses to the COVID-19 crisis

Dosi, Giovanni - In: Intereconomics : review of European economic policy 56 (2021) 6, pp. 337-340

This article discusses the medical/therapeutical responses to the COVID-19 pandemic and their political economy context. First, the very quick development of several vaccines highlights the richness of the basic knowledge waiting for therapeutical exploitation. Such knowledge has largely...

Persistent link: https://www.econbiz.de/10012803399